| Date23.05.2018 |
TitleVFMCRP AND CARA THERAPEUTICS TO DEVELOP AND COMMERCIALISE CR845 INJECTION FOR CHRONIC KIDNEY DISEASE-ASSOCIATED PRURITUS |
| Date15.05.2018 |
Title90TH VIFOR PHARMA GROUP ANNUAL SHAREHOLDER MEETING |
| Date08.05.2018 |
TitleUS FDA APPROVES USE OF VELTASSA® WITH OR WITHOUT FOOD |
| Date29.03.2018 |
TitleVIFOR PHARMA TO PROPOSE JACQUES THEURILLAT AS BOARD MEMBER |
| Date27.03.2018 |
TitleVIFOR PHARMA CONCLUDES LICENSING AGREEMENT WITH ZERIA TO MARKET VELTASSA® IN JAPAN |
| Date15.03.2018 |
TitleVIFOR PHARMA GROUP REPORTS STRONG 2017 RESULTS, EXCEEDING RAISED GUIDANCE |
| Date08.02.2018 |
TitleVIFOR PHARMA FERROPORTIN INHIBITOR ENTERS PHASE-I CLINICAL TRIAL |
| Date04.01.2018 |
TitleAVACOPAN CONDITIONAL MARKETING AUTHORIZATION APPLICATION ACCEPTED FOR REGULATORY REVIEW BY EUROPEAN MEDICINES AGENCY |
| Date04.01.2018 |
TitleVELTASSA® APPROVED FOR MARKETING IN SWITZERLAND FOR THE TREATMENT OF HYPERKALAEMIA |